Compositions of therapeutic substances, methods and uses thereof
AssigneeElka Touitou
InventorElka Touitou
Life of this patent
Estimating the term…
Abstract
Provided is a composition for oral administration which includes a lipophilic active substance and a phospholipid, providing a prolonged therapeutic effect.
Claims24
A prolonged release oral pharmaceutical formulation in the form of a solid or semisolid compact mass, consisting of:
- at least one cannabinoid;
- at least one phospholipid, said at least one cannabinoid being solubilized in said at least one phospholipid;
- and
- optionally, at least one additive selected from the group consisting of an antioxidant, a surfactant, a taste masking agent, a color-imparting agent, a flavor-imparting agent, a viscosity increasing or viscosity decreasing agent, a salt, and any combination thereof,
- wherein said at least one phospholipid constitutes from 60-90 wt % of the formulation and the formulation is free of water and fat glycerides, and
- wherein said formulation is in the form of a solid or semisolid compact mass in unit dosage form, optionally encapsulated, from which, when administered orally, said cannabinoid diffuses for at least 10 hours so as to provide a prolonged therapeutic effect of at least 10 hours.
A prolonged effect pharmaceutical formulation in the form of a solid or semisolid compact mass, consisting of:
- at least one cannabinoid;
- at least one phospholipid, wherein said cannabinoid is solubilized in said phospholipid;
- and
- an additive selected from the group consisting of an antioxidant, a surfactant, a taste masking agent, a color- or a flavor-imparting agent, a viscosity increasing or viscosity decreasing agent, and a salt,
- wherein said at least one phospholipid constitutes from 60-90 wt % of the formulation, and the formulation is free of water and fat glycerides, and
- wherein said formulation is in the form of a solid or semisolid compact mass in unit dosage form, optionally encapsulated, from which, when administered orally, said cannabinoid diffuses for at least 10 hours so as to provide a prolonged therapeutic effect of at least 10 hours.
A prolonged release oral pharmaceutical formulation in the form of a solid or semisolid compact mass, comprising:
- at least one cannabinoid;
- and
- at least one phospholipid, said at least one cannabinoid being solubilized in said at least one phospholipid,
- wherein said at least one phospholipid constitutes from 60-90 wt % of the formulation and the formulation is free of water and fat glycerides, and
- wherein said formulation is in the form of a solid or semisolid compact mass in unit dosage form, from which, when administered orally, said cannabinoid diffuses for at least 10 hours so as to provide a prolonged therapeutic effect of at least 10 hours.
A prolonged release oral pharmaceutical formulation in the form of a solid or semisolid compact mass, comprising at least one cannabinoid and at least one phospholipid and no more than 5% solvent, the formulation being free of water and fat glycerides, said at least one phospholipid comprising from 60-90 wt % of the formulation, said formulation being produced by the process comprising:
- thoroughly mixing said at least one cannabinoid, said phospholipid, and said solvent, if present, at a w/w ratio selected to produce a solid or semisolid compact mass that is free of water and fat glycerides;
- and
- shaping said compact viscous mass into solid or semisolid dosage form units from which, when orally administered, said cannabinoid diffuses for at least 10 hours so as to have a prolonged therapeutic effect of at least 10 hours.
Dependencies are inferred from the claim text.